Ascites is the most frequent complication of liver cirrhosis and results in increased
morbidity and mortality but current medical management options are limited. Here, the
investigators will conduct an interventional single-arm pilot clinical trial toevaluate the
feasibility of empagliflozin in managing diuretic-resistant ascites in patients with
decompensated cirrhosis. This single site, open label pilot study will enroll participants
with decompensated cirrhosis at a single site. Participants will receive empagliflozin 10mg
oral tablets once daily for 12 weeks with monitoring for safety and adverse events.